Table 3 Information on patient follow-up
Indicators | Enrollment % (n) | Follow-up at 6 months % (n) | Follow-up at 12 months % (n) |
|---|---|---|---|
Total no. of participants (N) | 106 | 80 | 82 |
Symptoms of VL | |||
Fever > 2 weeks | 4 (3.8) | 1 (1.3) | 0 |
Loss of appetite | 3 (2.8) | 3 (3.8) | 1 (1.2) |
Perceived loss of weight | 4 (3.8) | 3 (3.8) | 1 (1.2) |
Abdominal enlargement/Splenomegaly | 3 (2.8) | 2 (2.5) | 2 (2.4) |
No. of suspected VL patient | 0 | 0 | 0 |
No. of reported relapse case of VL within the study period | 5 (4.7) | 1 | 2 |
Symptoms of PKDL | |||
Lesion on the face, neck, upper and lower limbs | 8 (7.5) | 0 | 0 |
Papules/nodules of skin on the face, neck, upper and lower limbs | 0 | 0 | 0 |
No. of PKDL patient | 1 | 1 | 0 |
Weight (in Kg) (Median, Min.-Max.) | 27.5 (7–115) | 27.2 (7–119) | 30 (10–117) |
Hemoglobin (mg/dl) (mean ± SD) | 12.3 ± 2.5 | 11.6 ± 1.9 | 12.8 ± 1.8 |